Novel markers of COVID-19 mortality-A comparative study with patients of acute coronary syndrome.
Acute coronary syndrome
COVID-19
biomarkers
total leukocyte count
Journal
Journal of family medicine and primary care
ISSN: 2249-4863
Titre abrégé: J Family Med Prim Care
Pays: India
ID NLM: 101610082
Informations de publication
Date de publication:
May 2023
May 2023
Historique:
received:
17
08
2022
revised:
22
11
2022
accepted:
16
01
2023
medline:
14
7
2023
pubmed:
14
7
2023
entrez:
14
7
2023
Statut:
ppublish
Résumé
COVID-19 can cause severe pneumonia that can progress to multiple organ failure. It is believed that dysregulation of inflammation and cytokine storm, contributes to severe COVID-19. As inflammatory mediators play an important role in the pathogenesis of the severe disease, inflammatory markers like fever, leucocytosis, and C-reactive protein are known to predict severe disease. Various other biomarkers have been known to have prognostic value in patients with COVID-19 infection. Inflammation, both local and systemic plays an important role in the pathogenesis of acute coronary syndrome (ACS). Thus in this study, we aimed to compare and describe the various biomarkers, and mortality between patients admitted with COVID-19 infection and ACS patients without COVID-19 infection. In a retrospective observational case-control study, a total of 108 patients admitted to our hospital during the month of May 2021 with COVID-19 were enrolled. Patients of the acute coronary syndrome (tested negative for COVID-19 infection) admitted during the same month were enrolled (including both the intensive care unit and ward) as controls. The median age of patients with COVID was significantly lower than that of patients with acute coronary syndrome [49 years (IQR, 36-62 years) and 60 years (IQR, 52-66 years)]. Left ventricular ejection fraction was significantly higher among patients with COVID infection (58.5 ± 6.3% versus 36.9 ± 9.3%). The total leukocyte count was significantly higher among patients with COVID-19 compared to those with acute coronary syndrome [13200 per microliter (8625-17500) vs 9800 per microliter (8150-12150), Elevated total leukocyte counts reflect underlying secondary bacterial infection among patients with COVID-19 and help initiate appropriate antibiotics. Depletion of intravascular volume reflected by an increased urea/creatinine ratio increases the risk of mortality and warrants aggressive measures of rehydration and albumin infusion.
Sections du résumé
Background
UNASSIGNED
COVID-19 can cause severe pneumonia that can progress to multiple organ failure. It is believed that dysregulation of inflammation and cytokine storm, contributes to severe COVID-19. As inflammatory mediators play an important role in the pathogenesis of the severe disease, inflammatory markers like fever, leucocytosis, and C-reactive protein are known to predict severe disease. Various other biomarkers have been known to have prognostic value in patients with COVID-19 infection. Inflammation, both local and systemic plays an important role in the pathogenesis of acute coronary syndrome (ACS). Thus in this study, we aimed to compare and describe the various biomarkers, and mortality between patients admitted with COVID-19 infection and ACS patients without COVID-19 infection.
Methods
UNASSIGNED
In a retrospective observational case-control study, a total of 108 patients admitted to our hospital during the month of May 2021 with COVID-19 were enrolled. Patients of the acute coronary syndrome (tested negative for COVID-19 infection) admitted during the same month were enrolled (including both the intensive care unit and ward) as controls.
Results
UNASSIGNED
The median age of patients with COVID was significantly lower than that of patients with acute coronary syndrome [49 years (IQR, 36-62 years) and 60 years (IQR, 52-66 years)]. Left ventricular ejection fraction was significantly higher among patients with COVID infection (58.5 ± 6.3% versus 36.9 ± 9.3%). The total leukocyte count was significantly higher among patients with COVID-19 compared to those with acute coronary syndrome [13200 per microliter (8625-17500) vs 9800 per microliter (8150-12150),
Conclusions
UNASSIGNED
Elevated total leukocyte counts reflect underlying secondary bacterial infection among patients with COVID-19 and help initiate appropriate antibiotics. Depletion of intravascular volume reflected by an increased urea/creatinine ratio increases the risk of mortality and warrants aggressive measures of rehydration and albumin infusion.
Identifiants
pubmed: 37448943
doi: 10.4103/jfmpc.jfmpc_1629_22
pii: JFMPC-12-962
pmc: PMC10336926
doi:
Types de publication
Journal Article
Langues
eng
Pagination
962-966Informations de copyright
Copyright: © 2023 Journal of Family Medicine and Primary Care.
Déclaration de conflit d'intérêts
There are no conflicts of interest.
Références
Indian Heart J. 2019 Sep - Oct;71(5):387-393
pubmed: 32035521
Sci Rep. 2020 Sep 24;10(1):15649
pubmed: 32973256
N Engl J Med. 2008 Feb 28;358(9):954-6
pubmed: 18305271
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Asian Cardiovasc Thorac Ann. 2021 Oct;29(8):751-757
pubmed: 33444068
Int Immunol. 2010 May;22(5):347-52
pubmed: 20410258
J Clin Virol. 2020 Jun;127:104370
pubmed: 32344321
Infect Immun. 2008 Feb;76(2):454-65
pubmed: 18086818
Indian J Med Res. 2021 Jan & Feb;153(1 & 2):7-16
pubmed: 33818464
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
J Med Virol. 2021 Feb;93(2):786-793
pubmed: 32662893
J Infect. 2016 Nov;73(5):468-475
pubmed: 27519621
Infection. 2020 Apr;48(2):241-248
pubmed: 31873850
J Infect Dis. 2019 Aug 30;220(7):1166-1171
pubmed: 31115456
Lancet. 2020 May 9;395(10235):1517-1520
pubmed: 32311318
Clin Chim Acta. 2020 Oct;509:91-94
pubmed: 32511972
JAMA. 1995 Sep 27;274(12):968-74
pubmed: 7674528
Indian Heart J. 2021 Mar-Apr;73(2):174-179
pubmed: 33865514
Clin Infect Dis. 2020 Jul 28;71(15):762-768
pubmed: 32161940
J Clin Invest. 2003 Jun;111(12):1805-12
pubmed: 12813013
Clin Chim Acta. 2020 Oct;509:235-243
pubmed: 32533986
PLoS Pathog. 2013 Feb;9(2):e1003188
pubmed: 23468627
Transfus Apher Sci. 2020 Dec;59(6):102926
pubmed: 32893135
J Infect. 2020 Jun;80(6):607-613
pubmed: 32283152
Int J Lab Hematol. 2020 Jun;42 Suppl 1:11-18
pubmed: 32311826
EJHaem. 2021 May 06;2(3):319-326
pubmed: 34226904
BMJ Case Rep. 2021 May 27;14(5):
pubmed: 34045206
Hematol Transfus Cell Ther. 2020 Apr - Jun;42(2):116-117
pubmed: 32284281
J Crit Care. 2008 Dec;23(4):557-64
pubmed: 19056023
Chest. 2009 Nov;136(5):1237-1248
pubmed: 19696123